Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients
Go back to Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients| CEL-SCI CORPORATION (NYSE: CVM) | Delayed: 1.67 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.67 | 52 Week High | $0.66 | |||
| Open | $1.70 | 52 Week Low | $0.20 | |||
| Day High | $1.70 | P/E | N/A | |||
| Day Low | $1.66 | EPS | $-0.34 | |||
| Volume | 34,379 | |||||
